GlassScriptPhysician profile
Janet D Howell
NPI 1578735502
$3,495.96
in general payments reported to CMS, 2019-2025
37 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $97.33 · 2023: $1,284 · 2024: $1,901 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,398.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $438.22 | 2023-2024 | |
| Lilly USA, LLC | $412.92 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $283.47 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $273.55 | 2023-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $189.82 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.37 | 2023-2024 | Jardiance |
| Pfizer INC. | $171.10 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.07 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.94 | 2022-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $104.12 | 2023-2024 | Trintellix |
| Novartis Pharmaceuticals Corporation | $103.81 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $97.26 | 2024-2025 | Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $95.35 | 2022-2023 | |
| Boston Scientific Corporation | $88.42 | 2024-2025 | Watchman Flx, Bodyguardian |
| Teva Pharmaceuticals USA, INC. | $73.83 | 2024-2025 | Ajovy, Austedo Xr |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $56.67 | 2023-2024 | Nuzyra |
| Astellas Pharma US INC | $55.98 | 2024 | Veozah |
| Heartflow, INC. | $48.83 | 2023-2024 | Ffrct |
| Abbott Laboratories | $46.63 | 2023 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $44.20 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $43.45 | 2023-2024 | Verquvo, Belsomra |
| Corium, LLC | $40.45 | 2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $36.07 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $34.92 | 2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $34.59 | 2024 | Xarelto |
| Antares Pharma, INC. | $32.95 | 2024-2025 | Xyosted |
| Ultragenyx Pharmaceutical INC. | $30.96 | 2022 | |
| Cvrx, INC. | $30.89 | 2023 | Barostim Neo System |
| Philips North America LLC | $29.57 | 2023 | |
| Edwards Lifesciences Corporation | $28.68 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Exact Sciences Corporation | $28.62 | 2024 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $26.65 | 2022 | |
| Dexcom, INC. | $24.18 | 2024 | Dexcom G6 Transmitter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.84 | 2023 | Lifevest |
| Viatris Specialty LLC | $13.73 | 2025 | Yupelri |
| Smith+Nephew, INC. | $13.11 | 2024 | Collagenase Santyl |
| Phathom Pharmaceuticals, INC. | $9.74 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.